BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18190680)

  • 1. Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.
    Journé F; Kheddoumi N; Chaboteaux C; Duvillier H; Laurent G; Body JJ
    Breast Cancer Res; 2008; 10(1):R4. PubMed ID: 18190680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
    Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
    Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
    Journe F; Chaboteaux C; Magne N; Duvillier H; Laurent G; Body JJ
    Breast Cancer Res; 2006; 8(1):R2. PubMed ID: 16417650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates induce breast cancer cell death in vitro.
    Fromigue O; Lagneaux L; Body JJ
    J Bone Miner Res; 2000 Nov; 15(11):2211-21. PubMed ID: 11092402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
    Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
    Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
    Inoue S; Arai N; Tomihara K; Takashina M; Hattori Y; Noguchi M
    Eur J Pharmacol; 2015 Aug; 761():44-54. PubMed ID: 25934567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
    Patel JB; Mehta J; Belosay A; Sabnis G; Khandelwal A; Brodie AM; Soprano DR; Njar VC
    Br J Cancer; 2007 Apr; 96(8):1204-15. PubMed ID: 17387344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells.
    Merrell MA; Wakchoure S; Ilvesaro JM; Zinn K; Gehrs B; Lehenkari PP; Harris KW; Selander KS
    Eur J Pharmacol; 2007 Mar; 559(1):21-31. PubMed ID: 17214981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
    Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
    Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells.
    Park YE; Bava U; Lin JM; Cornish J; Naot D; Reid IR
    Calcif Tissue Int; 2019 Nov; 105(5):497-505. PubMed ID: 31324954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
    Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
    Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines.
    Journé F; Magné N; Chaboteaux C; Kinnaert E; Bauss F; Body JJ
    Clin Exp Metastasis; 2006; 23(2):135-47. PubMed ID: 16912915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.
    Ibrahim T; Liverani C; Mercatali L; Sacanna E; Zanoni M; Fabbri F; Zoli W; Amadori D
    Int J Oncol; 2013 Apr; 42(4):1263-70. PubMed ID: 23403907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
    Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
    Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
    Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
    Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
    Vogt U; Bielawski KP; Bosse U; Schlotter CM
    Oncol Rep; 2004 Nov; 12(5):1109-14. PubMed ID: 15492801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
    Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
    J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
    Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
    Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.